Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -140.72M | -38.85M | -42.68M | -52.20M | -191.94M |
| Total Depreciation and Amortization | 2.40M | 2.57M | 3.14M | 3.44M | 5.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105.40M | 7.84M | 5.97M | 3.57M | 139.63M |
| Change in Net Operating Assets | 672.00K | -136.00K | -876.00K | -9.55M | 34.00K |
| Cash from Operations | -32.25M | -28.58M | -34.46M | -54.74M | -47.24M |
| Capital Expenditure | -304.00K | -62.00K | -168.00K | -246.00K | -44.00K |
| Sale of Property, Plant, and Equipment | 24.00K | 263.00K | -- | -- | -- |
| Cash Acquisitions | -41.20M | -- | -- | -- | -31.35M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.11M | 3.15M | 12.82M | 69.71M | 84.90M |
| Cash from Investing | -31.37M | 3.35M | 12.65M | 69.47M | 53.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 223.00K | 50.00M | 184.00K | -- | 437.00K |
| Repurchase of Common Stock | -1.00K | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1.00K | 1.00K | -- |
| Cash from Financing | 222.00K | 50.00M | 183.00K | 1.00K | 437.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.39M | 24.77M | -21.63M | 14.73M | 6.70M |